Researchers report that semaglutide, the active ingredient in GLP‑1 drugs such as Ozempic and Wegovy, may help reverse tissue damage in osteoarthritis by reprogramming the metabolism of cells that make and maintain cartilage. A study published March 3 in Cell Metabolism found that semaglutide improved cartilage energy generation and promoted tissue repair through mechanisms that appear at least partly independent of weight loss.
GLP‑1 drugs and osteoarthritis
GLP‑1 receptor agonists come in two chemical groups: one includes tirzepatide (sold as Mounjaro and Zepbound) and the other includes semaglutide (sold as Ozempic and Wegovy). Both groups reduce appetite and are effective for weight loss — a known way to lessen osteoarthritis symptoms by reducing joint load and inflammation. The new research asked whether benefits of GLP‑1 drugs extend beyond weight loss.
Key findings
– In obese mice with osteoarthritis, semaglutide treatment produced better cartilage protection than controls despite similar weight loss between groups.
– In a small human study of 20 people (ages 50–75; seven men, 13 women) with obesity and osteoarthritis, participants treated with semaglutide for 24 weeks showed significant improvements in knee function.
– MRI analyses in the treated group revealed thicker cartilage and signs of recent cartilage growth in inner joint areas.
– The proposed mechanism involves altering metabolic pathways in chondrocytes and other joint cells so cartilage can generate more energy and enable repair, a weight‑loss‑independent effect.
Expert perspective
Matthew Baker, MD (Stanford), who was not involved in the study, said the work offers a hypothesis for disease‑modifying osteoarthritis therapies, noting most current treatments target symptoms rather than structural drivers. Bert Mandelbaum, MD (Cedars‑Sinai), also not involved in the study, suggested healthier cellular metabolism may preserve cartilage and that semaglutide likely stabilizes cartilage and enables limited repair by improving the joint’s metabolic environment.
About osteoarthritis
Osteoarthritis is a degenerative, inflammatory joint condition caused by progressive cartilage and joint damage. Common symptoms include:
– Joint pain or stiffness
– Loss of flexibility and reduced range of motion
– Tenderness with pressure
– Grating or clicking during movement
– Bone spurs
Risk factors include:
– Genetics
– Past joint injuries
– Age (risk rises after 50)
– Menopause
– Occupations with repeated kneeling, climbing, or heavy lifting
– Obesity
Weight is a major modifiable driver of osteoarthritis, particularly in the knees. Excess body mass increases mechanical load across joints, accelerating cartilage wear. Cartilage has limited intrinsic healing capacity because it is avascular and low in cells, and osteoarthritis involves heterogeneous biological processes across cartilage, bone, synovium, nerves, and systemic metabolic factors.
Lifestyle strategies to reduce risk and symptoms
Experts recommend:
– Maintaining a healthy body weight
– Regular exercise, including low‑impact aerobic activity and strength training
– Adopting a plant‑forward diet (for example, Mediterranean patterns)
– Limiting alcohol
– Preventing joint injuries through balance training and appropriate footwear
– Managing metabolic conditions such as diabetes and insulin resistance to lower systemic inflammatory and metabolic stress on joint tissues
Broader context of GLP‑1 benefits
This research joins other studies suggesting GLP‑1 drugs have effects beyond weight loss. Earlier work has linked GLP‑1s to reduced inflammation and lower cancer risk (2023), better outcomes in certain heart failure patients (2025), reduced cardiovascular risk in people with type 2 diabetes (2025), and a possible reduction in diabetes‑related eye disease risk with tirzepatide‑containing drugs (February 2026).
Limitations and next steps
The new study is limited by small human sample size and scope. Researchers and outside experts emphasize the need for larger, longer trials to confirm semaglutide’s cartilage‑protective and disease‑modifying potential, delineate mechanisms, and determine who might benefit most. For now, weight loss and lifestyle measures remain primary, evidence‑based approaches to preventing and slowing osteoarthritis progression.
